| Anocca–SEVERAL: investment, 202107 financing round Series B SEK400m ($47m) led by Danske Bank |
2021-07-22 |
| Fertin Pharma–Philip Morris: investment, 202107– acquisition DKK5.1b ($820m) from EQT + Bagger-Sørensen ANNOUNCED |
2021-07-01 |
| Discover Echo–Cellink: investment, 202106– acquisition $110m with $98m in cash + $12m in new Series B shares ANNOUNCED |
2021-06-26 |
| Owler–Meltwater: investment, 202106– acquisition $24.5m with $18.9m in cash + $5.6m in equity ANNOUNCED |
2021-06-18 |
| Aldevron–Danaher: investment, 202106– acquisition $9.6b in cash by Danaher ANNOUNCED |
2021-06-17 |
| Kahr-Medical–Flerie Invest: investment, 202106 financing round totalling $46.5m incl existing + co-investor Flerie Invest AB |
2021-06-16 |
| Kahr-Medical–SEVERAL: investment, 202106 financing round $46.5m led by aMoon |
2021-06-16 |
| AstraZeneca–Proteros: small-molecule cancer drugs, 202106– collab r+d + license agreem with research funding + $62m milestones + royalties |
2021-06-02 |
| Origin.bio–EQT: investment, 202105 financing round totalling $15m incl lead investor EQT Ventures |
2021-05-26 |
| Origin.bio–PERSON: investment, 202105 financing round totalling $15m incl new + co-investor Sten Tamkivi |
2021-05-26 |
| Origin.bio–PERSON: investment, 202105 financing round totalling $15m incl new + co-investor Taavet Hinrikus |
2021-05-26 |
| Origin.bio–SEVERAL: investment, 202105 financing round $15m led by EQT Ventures |
2021-05-26 |
| Numab–Novo Group: investment, 202105 financing round Series C totalling CHF100m incl new + co-lead investor Novo Holdings |
2021-05-20 |
| Numab–SEVERAL: investment, 202105 financing round Series C CHF100m co-led by new investors Novo Holdings + HBM Partners |
2021-05-20 |
| Nanoscribe–Cellink: investment, 202105 acquisition 100% of Nanoscribe Holding for preliminary €36.9m with €24.7m cash + €12.2m in Series B shares |
2021-05-19 |
| Hummingbird Bioscience–Novo Group: investment, 202105 financing round Series C totalling $125m incl lead investor Novo Holdings |
2021-05-18 |
| Hummingbird Bioscience–SEVERAL: investment, 202105 financing round Series C $125m led by Novo Holdings |
2021-05-18 |
| AMSilk–Novo Group: investment, 202105 financing round Series C totalling €29m incl new + lead investor Novo Growth |
2021-05-11 |
| AMSilk–SEVERAL: investment, 202105 financing round Series C €29m led by Novo Growth with Cargill + ER Capital Holdings + MIG AG + Athos KG |
2021-05-11 |
| Cytoki Pharma–+ND Capital: investment, 202105 financing round Series A totalling $45m incl co-investor +ND Captial |
2021-05-05 |
| Cytoki Pharma–BPCE: investment, 202105 financing round Series A totalling $45m incl co-investor Seventure Partners |
2021-05-05 |
| Cytoki Pharma–Lundbeck: investment, 202105 financing round Series A totalling $45m incl existing + lead investor Lundbeckfonden Emerge |
2021-05-05 |
| Cytoki Pharma–SEVERAL: investment, 202105 financing round Series A $45m led by existing investor Lundbeckfonden Emerge |
2021-05-05 |
| Cytoki Pharma–Ysios Capital: investment, 202105 financing round Series A totalling $45m incl co-investor Ysios Capital |
2021-05-05 |
| Oculis–SEVERAL: investment, 202105 financing round Series C $57m co-led by new investors BVCF Management + Hyfinity Investments |
2021-05-04 |
| Adcendo–Gilde Investment: investment, 202104 financing round Series A totalling €51m incl co-investor Gilde Healthcare |
2021-04-29 |
| Adcendo–Novo Group: investment, 202104 financing round Series A totalling €51m incl co-lead investor Novo Seeds |
2021-04-29 |
| Adcendo–Odlander Fredrikson: investment, 202104 financing round Series A totalling €51m incl co-investor RA HealthCap |
2021-04-29 |
| Adcendo–Optimum Strategic Communications: public relations, 202104 service existent by Optimum |
2021-04-29 |
| Adcendo–RA Capital: investment, 202104 financing round Series A totalling €51m incl co-investor RA Capital Management |
2021-04-29 |
| Adcendo–SEVERAL: investment, 202104 financing round Series A €51m co-led by Novo Seeds + Ysios Capital |
2021-04-29 |
| Adcendo–Ysios Capital: investment, 202104 financing round Series A totalling €51m incl co-lead investor Ysios Capital |
2021-04-29 |
| Exscientia–Novo Group: investment, 202104 financing round Series D totalling $225m incl existing + co-investor Novo Holdings |
2021-04-27 |
| Exscientia–SEVERAL: investment, 202104 financing round Series D $225m led by SoftBank Vision Fund 2 |
2021-04-27 |
| Alligator Bioscience–MacroGenics: antibody cancer drug, 202104– collab research using Neo-X-Prime plus DART+TRIDENT technologies against two targets |
2021-04-15 |
| Mobidiag–Hologic: investment, 202104– acquisition €600m in cash ANNOUNCED |
2021-04-08 |
| Step Pharma–Hadean Ventures: investment, 202103 financing round Series B totalling €35m incl new + co-lead investor Hadean Ventures |
2021-03-24 |
| Step Pharma–SEVERAL: investment, 202103 financing round Series B €35m co-led by new investors Hadean Ventures + Sunstone Life Science Ventures |
2021-03-24 |
| Step Pharma–Sunstone Life Science: investment, 202103 financing round Series B totalling €35m incl new + co-lead investor Sunstone Life Science |
2021-03-24 |
| Aura Biosciences–SEVERAL: investment, 202103 financing round $80m led by Matrix Capital Management + Surveyor Capital |
2021-03-22 |
| Cellink–SEVERAL: credit, 202103–202603 convertible bonds SEK1.5b at 2.875%pa convertible into B Class shares at SEK598.5/share |
2021-03-12 |
| Cellink–SEVERAL: investment, 202103 capital increase SEK1.5b directed issue of new Class B Shares at SEK420/share |
2021-03-12 |
| MatTek–Cellink: investment, 202103– acquisition $68m net of cash/debt with $54.4m in cash + $13.6m in shares ANNOUNCED |
2021-03-10 |
| BioPhero–DCVC: investment, 202103 financing round Series A totalling $17m incl new + lead investor DCVC Bio |
2021-03-09 |
| BioPhero–FMC: investment, 202103 financing round Series A totalling $17m incl new + co-investor FMC Ventures |
2021-03-09 |
| BioPhero–Novo Group: investment, 202103 financing round Series A totalling $17m incl existing + co-investor Novo Holdings |
2021-03-09 |
| BioPhero–SEVERAL: investment, 202103 financing round Series A $17m led by DCVC Bio with FMC Ventures + Syngenta Ventures + Novo Holdings |
2021-03-09 |
| BioPhero–Syngenta: investment, 202103 financing round Series A totalling $17m incl existing + co-investor Syngenta Ventures |
2021-03-09 |
| Exscientia–BlackRock: investment, 202103 financing round Series C extension totalling $40m + closing at total of $100m incl new investor BlockRock |
2021-03-04 |
| Exscientia–SEVERAL: investment, 202103 financing round Series C extension $40m + closing at total of $100m with BlockRock joining existing investors |
2021-03-04 |
| Oxular–NeoMed: investment, 202103 financing round totalling £27m incl existing + co-investor NeoMed |
2021-03-01 |
| Oxular–SEVERAL: investment, 202103 financing round £27m led by Forbion |
2021-03-01 |
| Oxular–V-Bio Ventures: investment, 202103 financing round totalling £27m incl existing + co-investor V-Bio Ventures |
2021-03-01 |
| Tetramer Shop–10x Genomics: investment, 202102 acquisition €na of Tetramer Shop ApS by 10x Genomics Inc |
2021-02-24 |
| Altasciences–Novo Group: investment, 202102– acquisition of Altasciences by Novo Holdings from Audax Private Equity ANNOUNCED |
2021-02-22 |
| Almirall–MC2 Therapeutics: Wynzora Cream, 202102– license excl to commercialise Wynzora Cream for plaque psoriasis in Europe for Almirall |
2021-02-17 |
| Cognate BioServices–Charles River: investment, 202102–202103 acquisition $875m in cash by Charles River |
2021-02-17 |
| Ginolis–Cellink: investment, 202102–202103 acquisition 100% of Ginolis debt/cash-free for €65.7m with €41.6m in cash + €24.1m in shares |
2021-02-15 |
| EnginZyme–SEB: investment, 202102 financing round Series A extension totalling €4.6m incl new + co-investor SEB Greentech VC |
2021-02-11 |
| EnginZyme–SEVERAL: investment, 202102 financing round Series A extension €4.6m led by Industrifonden + incl SEB Greentech VC + existing shareholders |
2021-02-11 |
| EnginZyme–Sweden (govt): investment, 202102 financing round Series A extension totalling €4.6m incl new + lead investor Industrifonden |
2021-02-11 |
| Evaxion Biotech–LifeSci: public relations, 202102 supply service existent by LifeSci Advisors LLC |
2021-02-10 |
| Evaxion Biotech–SEVERAL: investment, 202102 US IPO $30m+$4.5m with 3m+450k ADSs at $10/ADS at Nasdaq Capital Market |
2021-02-10 |
| IO Biotech–Avoro Capital: investment, 202101 financing round Series B totalling €127m incl new + co-investor Avoro Capital |
2021-01-13 |
| IO Biotech–Eurazeo: investment, 202101 financing round Series B totalling €127m incl new + co-investor Idinvest Partners |
2021-01-13 |
| IO Biotech–HBM: investment, 202101 financing round Series B totalling €127m incl new + lead investor HBM Healthcare Investments |
2021-01-13 |
| IO Biotech–Kurma: investment, 202101 financing round Series B totalling €127m incl new + co-investor Kurma Partners |
2021-01-13 |
| IO Biotech–Lundbeck: investment, 202101 financing round Series B totalling €127m incl existing+ co-investor Lundbeckfonden Emerge |
2021-01-13 |
| IO Biotech–Novo Group: investment, 202101 financing round Series B totalling €127m incl existing+ co-investor Novo Seeds |
2021-01-13 |
| IO Biotech–PFM Health Sciences: investment, 202101 financing round Series B totalling €127m incl new + co-investor PFM Health Sciences |
2021-01-13 |
| IO Biotech–RA Capital: investment, 202101 financing round Series B totalling €127m incl new + co-investor RA Capital Management |
2021-01-13 |
| IO Biotech–Samsara BioCapital: investment, 202101 financing round Series B totalling €127m incl new + co-investor Samsare BioCapital |
2021-01-13 |
| IO Biotech–Serrado Capital: investment, 202101 financing round Series B totalling €127m incl new + co-investor Serrada Capital |
2021-01-13 |
| IO Biotech–SEVERAL: investment, 202101 financing round Series B €127m led by new investor HBM Healthcare Investments |
2021-01-13 |
| IO Biotech–Soleus Capital: investment, 202101 financing round Series B totalling €127m incl new + co-investor Soleus Capital |
2021-01-13 |
| IO Biotech–Sunstone Life Science: investment, 202101 financing round Series B totalling €127m incl existing+ co-investor Sunstone Life Science |
2021-01-13 |
| IO Biotech–Vivo Capital: investment, 202101 financing round Series B totalling €127m incl new + co-investor Vivo Capital |
2021-01-13 |
| BioGeneration Ventures–Industriens Pension: investment, 202101 final closing of BGV IV totalling €140m incl investor Industriens Pension |
2021-01-07 |
| BioGeneration Ventures–Novo Group: investment, 202101 final closing of BGV IV totalling €140m incl investor Novo Ventures |
2021-01-07 |
| BioGeneration Ventures–SEVERAL: investment, 202101 final closing of BGV IV with €140m incl Lilly + Novo Ventures + BMS + Schroder Adveq et al |
2021-01-07 |
| CorWave–Novo Group: investment, 202101 financing round Series C totalling €35m incl existing + co-investor Novo Holdings |
2021-01-06 |
| CorWave–SEVERAL: investment, 202101 financing round Series C €35m led by new investor EIC Fund |
2021-01-06 |
| Faron Pharmaceuticals–Precision Medicine Group: public relations, 202101 service existent IR by Stern IR |
2021-01-04 |
| Immunicum–Van Herk: investment, 202012c largest shareholder holding 43% after merger of Immunicum with DCprime |
2020-12-31 |
| Hemab–Genmab: antibody technology, 202012 existent license to DuoBody platform to develop antibodies for bleeding disorders |
2020-12-14 |
| Hemab–Novo Group: antibody technology, 202012 existent license to IP to develop antibodies for bleeding disorders from Novo Nordisk AS |
2020-12-14 |
| Hemab–Novo Group: investment, 202012 seed investor Novo Seeds |
2020-12-14 |
| Evaxion Biotech–EU (govt): credit, 202012– EIB loan €20m under InnovFin program to advance AI-based vaccine research |
2020-12-09 |
| BioInnovation Institute–Novo Group: grant, 202012–203012 up to €470m funding over ten years to BBI from Novo Nordisk Foundation |
2020-12-08 |
| Osteolabs–MVZ Dr Krause: investment, 202012 2nd financing round totalling €1.6m incl existing investor Labor Dr Krause MVZ Kiel |
2020-12-08 |
| Osteolabs–Schleswig-Holstein (govt): investment, 202012 2nd financing round totalling €1.6m incl existing investor MGB Kiel Seed and Start-Up Fonds II |
2020-12-08 |
| Osteolabs–SEVERAL: investment, 202012 2nd financing round €1.6m from MGB Kiel + MVZ Dr Krause Kiel + SVM Hamburg |
2020-12-08 |
| Osteolabs–SVM (DE): investment, 202012 2nd financing round totalling €1.6m incl new investor SVM Verwaltungsgesellschaft mbH Hamburg |
2020-12-08 |
| Single Technologies–SEVERAL: investment, 202012 financing round €5m oversubscribed share issue with existing + new investors |
2020-12-04 |
| Enduro Genetics–BioInnovation Institute: credit, 202012 pre-seed loan €470k from BII |
2020-12-02 |
| Slack Technologies–Salesforce: investment, 202012– acquisition $27.7b in cash + shares of Slack by Salesforce ANNOUNCED |
2020-12-01 |
| SynOx Therapeutics–Odlander Fredrikson: investment, 202011 financing round Series A totalling €37m incl co-lead investor HealthCap |
2020-11-19 |
| SynOx Therapeutics–SEVERAL: investment, 202011 financing round Series A €37m co-led by HealthCap + Medicxi with Forbion + Gimv |
2020-11-19 |
| BioInvent–Van Herk: investment, 202011 existent Van Herk is largest shareholder of BioInvent |
2020-11-18 |
| DCprime–Immunicum: investment, 202011– merger with former Immunicum shareholders holding 56% + Van Herk holding 43% of combined company ANNOUNCED |
2020-11-18 |
![[LSS] Life-Sciences-Scandinavia.com - The Scandinavian Life Sciences Web Portal](/images/basics/lss-life-sciences-scandinavia-portal-logo-2019.png){kind=logo}
Date
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)
